Table 1.
Patient’s characteristics.
| Patient’s Characteristics | Overall Population n = 191 |
AMA + MMT n = 37 (19%) |
AMA + Non-MMT n = 37 (19%) |
p-Value * |
|---|---|---|---|---|
| Age | 0.1 | |||
| Median, years (range) | 61 (15–88) | 57 (24–88) | 61 (45–78) | |
| Sex | 0.35 | |||
| Female | 107 (56%) | 19 (51%) | 13 (35%) | |
| Male | 84 (44%) | 18 (49%) | 24 (65%) | |
| ECOG PS | 0.63 | |||
| 0 | 67 (35%) | 10 (27%) | 11 (30%) | |
| 1 | 93 (49%) | 21 (57%) | 23 (62%) | |
| ≥2 | 31 (16%) | 6 (16%) | 3 (8%) | |
| Smoking Status | 0.81 | |||
| Smoker (active or former) | 94 (49%) | 18 (49%) | 19 (51%) | |
| Missing | 17 (9%) | 2 (5%) | 3 (8%) | |
| Tumor Type | 0.84 | |||
| Lung | 88 (46%) | 18 (49%) | 17 (46%) | |
| Melanoma | 21 (11%) | 6 (16%) | 5 (14%) | |
| Breast | 19 (10%) | 7 (19%) | 4 (10%) | |
| Pancreas | 12 (6%) | 1 (3%) | 3 (8%) | |
| Sarcoma | 7 (4%) | 0 | 1 (3%) | |
| Colorectal | 7 (4%) | 1 (3%) | 2 (5%) | |
| Other | 37 (19%) | 4 (10%) | 5 (14%) | |
| Extension Stage | 1 | |||
| Metastatic | 180 (94%) | 36 (97%) | 35 (94%) | |
| Other | 11 (6%) | 1 (3%) | 2 (5%) | |
| Previous Systemic Treatment | 0.15 | |||
| Median (range) | 3 (0–10) | 3 (0–9) | 3 (0–7) | |
| Missing | 1 | 0 | 0 | |
| Subsequent Systemic Treatment | 0.73 | |||
| Median (range) | 1 (0–4) | 1 (1–3) | 1 (1–3) | |
| Missing | 32 | 0 | 0 | |
| Molecular Pathways Altered | ||||
| DNA damage repair system | - | 15 (41%) | 18 (49%) | 0.64 |
| RAS/RAF/MEK | - | 14 (38%) | 10 (27%) | 0.46 |
| PIK3CA/mTOR/AKT | - | 13 (35%) | 5 (14%) | 0.06 |
| ERBB/EGFR | - | 10 (27%) | 5 (14%) | 0.25 |
| Cell cycle | - | 3 (8%) | 5 (14%) | 0.71 |
| Other | - | 11 (30%) | 5 (14%) | 0.16 |
MA: actionable molecular alteration; MMT: molecularly matched therapy. * p-value is provided for comparison between groups: “AMA + MMT” vs. “AMA + non-MMT”.